Abbott Laboratories Initial Statement of Beneficial Ownership
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
3
Insider Trade Summary
4 transactions reported
Mixed
4 txns
Insider
Cushman Elizabeth C.
Role
EVP, GC AND SECRETARY
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Option (right to buy) | -- | -- | -- |
| holding | Option (right to buy) | -- | -- | -- |
| holding | Option (right to buy) | -- | -- | -- |
| holding | Common shares without par value | -- | -- | -- |
Holdings After Transaction:
Option (right to buy) — 40,762 contracts (Direct);
Common shares without par value — 21,436 shares (Direct)
Footnotes (3)
- F1. Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 3,479 on February 17, 2024, 3,480 on February 17, 2025, and 3,480 on February 17, 2026.
- F2. Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 3,239 on February 21, 2025, 3,239 on February 21, 2026, and 3,239 on February 21, 2027.
- F3. Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 6,868 on February 25, 2026, 6,869 on February 25, 2027 and 6,869 on February 25, 2028.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates